Compare Abbott Laboratories (ABT) vs Twilio Inc (TWLO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Twilio Inc — how do they compare? Abbott Laboratories trades at $95.24 (market cap $166.94B), while Twilio Inc trades at $212.68 (market cap $32.17B). The key difference: Abbott Laboratories is far larger — about 5.2× Twilio Inc's market cap, and Abbott Laboratories pays a 2.63% dividend while Twilio Inc pays none. Which is the better fit depends on your goals.
| ABT | TWLO | |
|---|---|---|
Market Cap | $166.94B | $32.17B |
Sector | Health | Technology |
52-Week High | $136.62 | $236.64 |
52-Week Low | $82.57 | $92.44 |
Enterprise Value | $193.69B | $30.89B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Twilio (TWLO) trades at $211.97, up 1.27% with bullish technical signals and strong analyst support. The stock shows improving fundamentals with revenue growth from $4.5B to $5.1B in 2025 and a return to profitability after years of losses. Recent earnings beats and AI-driven demand for cloud communications tools support positive momentum. Technical indicators show the stock trading near pivot point resistance at $210 with bullish moving average alignment.
Twilio presents a growth opportunity with margin expansion potential and AI adoption driving demand, though elevated valuation metrics (P/E 316.79) warrant caution. Key risks include competitive pressures in cloud communications and execution challenges in maintaining profitability growth. Analyst consensus remains strongly bullish with 75% buy ratings and $211.69 price target, suggesting balanced risk-reward near current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Twilio Inc
Twilio Inc. is a cloud-based communication platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces, or APIs, and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
Read more on TWLO →
